Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/ Progesterone Receptor (ER/PR) Positive Breast Cancer

This measure is to be reported for all female patients aged 18 years and older with breast cancer — a minimum of **once** per reporting period.

Measure description

Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER or PR positive breast cancer who were prescribed¹ tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period

What will you need to report for each female patient with breast cancer for this measure?

If you select this measure for reporting, you will report:

The ER and PR status AND the documented AJCC cancer stage of breast cancer

If the patient has Stage IC through IIIC, ER or PR positive breast cancer, you will then need to report:

Whether or not the patient is receiving tamoxifen or aromatase inhibitor²

What if this process or outcome of care is not appropriate for your patient?

There may be times when it is not appropriate to prescribe tamoxifen or aromatase inhibitor, due to:

- Medical reasons (eg, patient's disease has progressed to metastatic; patient is receiving a gonadotropin-releasing hormone analogue, patient has received oophorectomy, patient is receiving radiation or chemotherapy, patient's diagnosis date was ≥ 5 years from reporting date) OR
- Patient reasons (eg, patient refusal) OR
- System reasons (eg, patient is currently enrolled in a clinical trial)

In these cases, you will need to indicate which reason applies, and specify the reason on the worksheet and in the medical chart. The office/billing staff will then report a code with a modifier that represents these valid reasons (also called exclusions).

¹"Prescribed" includes patients who are currently receiving medication(s) that follow the treatment plan recommended at an encounter during the reporting period, even if the prescription for that medication was ordered prior to the encounter.

²The reporting clinician is not required to have written the initial prescription.

PQRI 2009 Measure 71, Effective Date 01/01/2009

^{© 2007} American Medical Association, American Society of Clinical Oncology, and National Comprehensive Cancer Network. All Rights Reserved. (Disclaimers, Copyright and other Notices indicated on the Coding Specifications document are incorporated by reference)